Entresto is a medication prescribed for heart failure with reduced ejection fraction (HFrEF) [1]. It is an angio-conversion enzyme neprilysin inhibitor (ARNI) and is prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure [1][2].
What are the active ingredients in Entresto?
Entresto is a combination medication containing sacubitril and valsartan [1][3]. Sacubitril is a neprilysin inhibitor, while valsartan is an angiotensin II receptor blocker (ARB) [3].
How does Entresto work?
Entresto works by blocking the breakdown of natriuretic peptides, which are naturally occurring substances in the body that help to reduce blood pressure and salt and water retention [2]. By inhibiting neprilysin, sacubitril increases the levels of these beneficial peptides. Valsartan, the ARB component, blocks the effects of angiotensin II, a hormone that narrows blood vessels and causes salt and water retention [3]. The combined action of sacubitril and valsartan helps to relax blood vessels, reduce blood pressure, and decrease the workload on the heart [2][3].
What dosages of Entresto are available?
Entresto is available in several dosage strengths, typically expressed as the sacubitril/valsartan ratio [4]. Common dosages include 24/26 mg, 49/51 mg, and 97/103 mg [4]. The starting dose and titration schedule are determined by a healthcare professional based on the individual patient's condition and tolerance [1].
What are the common side effects of Entresto?
Common side effects associated with Entresto include dizziness, low blood pressure (hypotension), cough, and elevated potassium levels (hyperkalemia) [1][3]. Patients may also experience fatigue, headache, and kidney problems [1].
Who should not take Entresto?
Entresto should not be used in individuals with a history of angioedema related to previous ARB or ARNI treatment [1]. It is also contraindicated in patients with concomitant use of aliskiren in patients with diabetes, and in pregnant women, as it can cause fetal injury or death [1][3]. Patients with hereditary angioedema should also avoid this medication [1].
When does Entresto patent expiry occur?
Information regarding the specific patent expiry dates for Entresto is available through specialized resources [5]. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can indicate when generic versions may become available [5].
How does Entresto compare to other heart failure medications?
Entresto has demonstrated superior efficacy compared to enalapril, an ACE inhibitor, in reducing cardiovascular mortality and hospitalization in patients with HFrEF [2]. Its dual mechanism of action, targeting both the natriuretic peptide system and the renin-angiotensin-aldosterone system (RAAS), differentiates it from single-acting RAAS inhibitors [3].
What clinical trials support the use of Entresto?
The pivotal PARADIGM-HF trial demonstrated that Entresto significantly reduced the risk of death from cardiovascular causes or hospitalization for heart failure compared to enalapril in patients with HFrEF [2].
What are the risks associated with Entresto treatment?
Key risks include angioedema, a potentially life-threatening swelling of the face, lips, tongue, throat, or extremities [1]. Hypotension, particularly in volume- or salt-depleted patients, and renal impairment are also potential concerns [1][3]. Careful monitoring of blood pressure, serum potassium, and renal function is recommended during treatment [1].
Can Entresto be used during pregnancy or breastfeeding?
Entresto is contraindicated during pregnancy due to the risk of fetal harm [1][3]. It is not recommended for use while breastfeeding [1].
---
Sources:
[1] https://www.novelmed.com/entresto-sacubitril-valsartan/
[2] https://www.heart.org/en/health-topics/heart-failure/treatment-options-for-heart-failure/medications-for-heart-failure
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697053/
[4] https://www.rxlist.com/entresto-drug.htm
[5] https://drugpatentwatch.com/